Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Aug;12(8):3918-3920.
doi: 10.21037/jtd.2020.04.45.

Programmed death-ligand 1 expression discrepancy between primary tumor and metastatic lymph nodes in non-small cell lung cancer

Waleed Kian  1   2 , Laila C Roisman  1   2 , Nadav Wallach  1   2 , Dina Levitas  1   2 , Alexander Yakobson  1   2 , Yulia Dudnik  1   2 , Nir Peled  1   2 , Keren Rouvinov  1   2
Affiliations
Editorial

Programmed death-ligand 1 expression discrepancy between primary tumor and metastatic lymph nodes in non-small cell lung cancer

Waleed Kian et al. J Thorac Dis. 2020 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/jtd.2020.04.45). NP reports grants and personal fees from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Foundation Medicine, Gaurdant360, Genesort, Merk, Merck Sharp & Dohme, Novartis, NovellusDx, Pfizer, Roche, Takeda, other from LOXO. The other authors have no conflicts of interest to declare.

Comment on

References

    1. Saito Y, Horiuchi S, Morooka H, et al. Inter-tumor heterogeneity of PD-L1 expression in non-small cell lung cancer. J Thorac Dis 2019;11:4982-91. 10.21037/jtd.2019.12.24 - DOI - PMC - PubMed
    1. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non–small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol 2019;37:537–46. 10.1200/JCO.18.00149 - DOI - PubMed
    1. Diker O. Pembrolizumab plus Chemotherapy in Lung Cancer. N Engl J Med 2018;379:e18. 10.1056/NEJMc1808567 - DOI - PubMed
    1. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med 2018;379:2040-51. 10.1056/NEJMoa1810865 - DOI - PubMed
    1. Kian W, Roisman LC, Levitas D, et al. Non-small cell lung cancer PDL1 >50%—should we go single or combo? Precis Cancer Med 2020;3:7. 10.21037/pcm.2019.11.08 - DOI